Monday, April 29, 2024

Moderna vaccine will come soon in the country, DCGI may get approval for emergency use

Moderna vaccine in India may get emergency use approval for people aged 18 years and above from the Drug Controller General of India (DCGI). Moderna has sought approval for its Kovid-19 vaccine in India. According to sources, Cipla has applied for import and marketing authorization of the vaccine regarding this.

Moderna’s vaccine approved for emergency use 

Moderna’ has also reported that the US government has agreed to donate doses of the ‘Moderna’ Kovid vaccine to the Indian government through ‘Covax’, which will be in a certain number. Approval has been sought from the Central Drugs Standard Control Organization (CDSCO) for these vaccines.

CDSCO can give approval at any time

‘Cipla’ has applied for the import and marketing of the vaccine on behalf of the American pharmaceutical company. According to sources, CDSCO can give approval at any time.

Cipla had on Monday moved an application seeking permission to import the ‘Moderna’ vaccine, citing DCGI’s notices dated April 15 and June 1. This notice said that if the vaccine is approved by the USFDA for the EU, then the vaccine can be given marketing authorization without a ‘bridging trial’.

Read More: The deadline for filing your income tax return has been extended; be sure you know everything you need to know before you file

The goal is to vaccinate as many people as possible

At the same time, on the matters of Corona, Health Minister Dr. Harsh Vardhan said that the vaccine is available for the last 6 months. Therefore, by following Kovid Appropriate Behavior and vaccinating more and more people, we can get success against Corona in the coming time.

Dr. Harsh Vardhan said that the second wave is not over yet. Cases have come down in Delhi, but our experience of one and a half years says that we should not be careless and should not sit comfortably.

40 times more deaths in the second wave

Let us tell you that the outbreak of the second wave of Coronavirus in the country has reduced now, but in a study done on the first and second wave, shocking figures have come to the fore. It has been revealed in the study that the death toll in the second wave of Kovid-19 was 40 times more than in the first wave.

Max Hospital has tried to see the difference between the first and second waves through an important study by combining the data of its 10 hospitals. In the second wave of Coronavirus, more deaths were seen in people below 45 years of age. Apart from this, some things in this study are very surprising.

It has been revealed in the study that most of the people who lost their lives due to the coronavirus had diabetes. Apart from this, the number of men in both the waves was very high. Apart from this, the use of steroids was equal in both waves.

spot_img
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Latest

Due to the new rule published by the DGCA, flight tickets will now be less expensive

You too may soon find relief from pricey plane tickets if bothered by the excessive trip costs. The Directorate General of Civil Aviation (DGCA)...

RBI bans Kotak Mahindra Bank! ban on new customers & issuance of credit card

The Reserve Bank of India has acted against Kotak Mahindra Bank, a significant private sector bank. The RBI has taken strong measures against Kotak...

Apple may introduce many products including new iPad in its special event on 7 May

Invites to a special Apple event on May 7th have begun to circulate. Regarding this occasion, the business also posted an image of an...

Indian Army Recruitment 2024 for Technical Graduate, know details

On its official website, the Indian Army published the notification for the 140th Technical Graduate Course (TGC-140) Recruitment. The recruiting campaign will fill a...

Bajaj to launch their biggest Pulsar bike! will launch on 3 May

The first teaser for the upcoming Bajaj Pulsar NS400 has been released by Bajaj Automotive. The launch date of this bike is set for...

Most Popular

Subscribe

* indicates required